Article
Reduced folate carrier-1 80G > A gene polymorphism is not associated with methotrexate treatment response in South Indian Tamils with rheumatoid arthritis.
Clinical rheumatology - 1 Apr 2016
Muralidharan Niveditha, Mariaselvam Christina Mary, Mithun C B, Negi Vir Singh
Abstract excerpt
Methotrexate (MTX) is the most commonly used disease-modifying drug to treat rheumatoid arthritis (RA). Although there are no reliable molecular markers to predict the treatment response and adverse effects to MTX therapy, the polymorphisms in genes coding for MTX metabolizing enzymes and transporters may play a crucial role. The reduced folate carrier-1 (RFC-1) is a bidirectional anion exchanger which transports...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
